Agenda
Philadelphia, 18 - 19 November 2025
Schedule
Create your personal agenda –check the favourite icon
Nov 188:55
Conference pass
Welcome
Keynotes
Chris Shanks, Content Director, Terrapinn Holdings Ltd
Nov 189:00
Conference pass
Chair's Opening Remarks
Keynotes
Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine
Nov 189:05
Conference pass
Keynote Panel Discussion: State of the Industry Address for Cell and Gene Therapies
Keynotes
Moderator: Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine
Miguel Forte, CEO, Kiji Tx
Arun Das, Chief Business Officer, Cabaletta Bio
Cokey Nguyen, President and CEO, Atara Biotherapeutics
Samarendra Mohanty, President and Chief Scientific Officer, Nanoscope Therapeutics
Huma Qamar, Chief Medical Officer, Ocugen
Anne Brooks, Senior Vice President, US Commercial, Iovance Biotherapeutics
Bennett Smith, SVP, General Manager, North America, Orchard Therapeutics
Nov 189:45
Conference pass
Leveraging cutting edge technologies to deliver next generation therapies for patients
Keynotes
Dan Kirby, Chief Commercial Officer, Iovance Biotherapeutics
Nov 1810:05
Conference pass
AAV Gene Therapy Research and CMC Considerations for Building and Executing a Competitive Pipeline
Keynotes
Morten Sogaard, President and Division Head, Gene Therapy Research and Technical Operations, Astellas Gene Therapies
Nov 1811:05
Conference pass
Chair's Remarks: Dara Missan, Staff Scientist, Process Development, Mayo Clinic
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Dara Missan, Staff Scientist, Process Development, Mayo Clinic
Nov 1811:05
Conference pass
Chair's Remarks: Frederic Bushman, Professor and Chair, Department of Microbiology, Co-Director PennCHOP Microbiome Program, Perelman School of Medicine at the University of Pennsylvania
Gene Therapy (Track 5, 120C)
Nov 1811:05
Conference pass
Chair's Remarks: Jenny Holt, CDO, Ray Therapeutics
Viral Vector Manufacturing (Track 7, 121 B)
Jenny Holt, Chief Development Officer, Ray Therapeutics
Nov 1811:05
Conference pass
Chair's Remarks: Justin Skoble, Vice President of Technical Operations, Caribou Biosciences, Inc.
Supply Chain & Logistics (Track 8, 121 C)
Nov 1811:05
Conference pass
Chair's Remarks: Deepu Madduri, Senior Director, Compound Development Team Lead, CARVYKTI, Johnson & Johnson
Cell Therapy (Track 1, Keynote Theatre)
Deepu Madduri, Senior Director, Compound Development Team Lead, CARVYKTI, Johnson & Johnson
Nov 1811:05
Conference pass
Chair's Remarks: Petter Björquist, CEO, VERIGRAFT
Innovation Showcase (Track 2, Seminar Theatre)
Petter Bjorquist, CEO, VERIGRAFT AB
Nov 1811:05
Conference pass
Chair's Remarks: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Evidence, Pricing & Access (Track 3, 120A)
Nov 1811:05
Conference pass
Chair's Remarks: Marcus Calkins, Director of Scientific Communication, GenomeFrontier Therapeutics, Inc.
Gene Modified Cell Therapy (Track 4, 120B)
Marcus Calkins, Director of Scientific Communication, Genomefrontier Therapeutics Inc
Nov 1811:10
Conference pass
Adding imaging reporting genes to viral vectors
Viral Vector Manufacturing (Track 7, 121 B)
Michael McMahon, Professor, John Hopkins School Of Medicine
Nov 1811:10
Conference pass
Clinical trials from start to finish: Achieving a joint approach to manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Dara Missan, Staff Scientist, Process Development, Mayo Clinic
Nov 1811:10
Conference pass
Novel Modifier Gene Therapy (Gene Agnostic): Cure to Blindness Diseases
Gene Therapy (Track 5, 120C)
Huma Qamar, Chief Medical Officer, Ocugen
Nov 1811:10
Conference pass
Supply chain strategies for allogenic cell therapies
Supply Chain & Logistics (Track 8, 121 C)
Nov 1811:10
Conference pass
CAR-T cells for medullary thyroid cancer
Cell Therapy (Track 1, Keynote Theatre)
Don Siegel, Director, Division of Transfusion Medicine & Therapeutic Pathology, Perelman School of Medicine University of Pennsylvania
Nov 1811:10
Conference pass
Precision gene therapy for heart failure
Innovation Showcase (Track 2, Seminar Theatre)
Matt Killeen, President, TikkunLev Therapeutics
Nov 1811:10
Conference pass
Update on the European and US Ecosystem for cell and gene therapies: What does the future of ATMP policy and access look like
Evidence, Pricing & Access (Track 3, 120A)
Nov 1811:10
Conference pass
Non-viral immune cell therapy for oncology & autoimmune diseases
Gene Modified Cell Therapy (Track 4, 120B)
Howard Wu, Co-Founder & Chief Scientific Officer, Full Circles Therapeutics
Nov 1811:50
Conference pass
Mechanisms and consequences of DNA integration
Gene Therapy (Track 5, 120C)
Nov 1811:50
Conference pass
Novel skills and competency-based workforce development: Empowering the GMP manufacturing ready talent pool
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Craig Hasilo, Chief Scientific Officer, Canadian Advanced Therapies Training Institute
Nov 1811:50
Conference pass
Operational aspects of manufacturing T cell-derived iPSCs
Supply Chain & Logistics (Track 8, 121 C)
Ruud Hulspas, Technical Director Process Development, Dana-Farber Cancer Institute
Nov 1811:50
Conference pass
Working with a CDMO to optimize vector functional titer
Viral Vector Manufacturing (Track 7, 121 B)
James Adams, Chief Technical Officer, Tr1x, Inc
Nov 1811:50
Conference pass
Leveraging the accelerated approval process for phase 1-3 trial development
Cell Therapy (Track 1, Keynote Theatre)
Joseph Stavas, Senior Vice President of Clinical Development, ProKidney
Nov 1811:50
Conference pass
Transforming Lives: How VERIGRAFT is Advancing Personalized Tissue Therapies for Serious Disease
Innovation Showcase (Track 2, Seminar Theatre)
Petter Bjorquist, CEO, VERIGRAFT AB
Nov 1811:50
Conference pass
Access and pricing considerations for commercialising advanced therapies
Evidence, Pricing & Access (Track 3, 120A)
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Nov 1811:50
Conference pass
Gene editing strategies for stem-cell derived therapies
Gene Modified Cell Therapy (Track 4, 120B)
Holger Russ, Associate Professor, University of Florida
Nov 1813:10
Conference pass
Chair's Remarks: Hemachandran Kannan, Director - AI Research Centre, Woxsen University
Supply Chain & Logistics (Track 8, 121 C)
Hemachandran Kannan, Director, Woxsen University
Nov 1813:10
Conference pass
Chair's Remarks: Michael Guerrero, Vice President of Technical Development and Operations, BridgeBio
Gene Therapy (Track 5, 120C)
Michael Guerrero, Vice President of Technical Development and Operations, BridgeBio
Nov 1813:10
Conference pass
Chair's Remarks: Nolan Polson, VP Quality Assurance and Product Quality, Iovance Biotherapeutics, inc.
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Nolan Polson, VP Quality Assurance and Product Quality, Iovance Biotherapeutics
Nov 1813:10
Conference pass
Chair's Remarks: Shadan Yarandi , Senior Scientist, Johnson & Johnson Innovative Medicine
Viral Vector Manufacturing (Track 7, 121 B)
Shadan Yarandi, Senior Scientist, Johnson & Johnson Innovative Medicine
Nov 1813:10
Conference pass
Chair's Remarks: David Morrow, Scientist, EATRIS
Innovation Showcase (Track 2, Seminar Theatre)
David Morrow, Scientist, EATRIS
Nov 1813:10
Conference pass
Chair's Remarks: Joanne Kurtzberg, Professor of Pediatrics & Pathology, Duke University School of Medicine
Cell Therapy (Track 1, Keynote Theatre)
Joanne Kurtzberg, Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Nov 1813:10
Conference pass
Chair's Remarks: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs
Evidence, Pricing & Access (Track 3, 120A)
Nov 1813:10
Conference pass
Chair's Remarks: Eric Hacherl, Chief Operating Officer, Kyttaro Therapeutics
Gene Modified Cell Therapy (Track 4, 120B)
Eric Hacherl, Chief Operating Officer, Kyttaro Therapeutics
Nov 1813:15
Conference pass
AAV gene therapy for cystic fibrosis
Gene Therapy (Track 5, 120C)
Roland Kolbeck, Chief Scientific Officer, Spirovant Sciences
Nov 1813:15
Conference pass
Comparative overview of logistical considerations for autologous and allogenic
Supply Chain & Logistics (Track 8, 121 C)
Christopher Ballas, Chief Technology Officer, Castle Creek Biosciences
Nov 1813:15
Conference pass
Manufacturing Innovation and Operational Excellence to Boost a Cell Therapy Development Engine
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Nelly Viseux, VP, Cell Therapies Development, Manufacturing, Supply & Quality, Regeneron
Nov 1813:15
Conference pass
Viral clearance
Viral Vector Manufacturing (Track 7, 121 B)
Shadan Yarandi, Senior Scientist, Johnson & Johnson Innovative Medicine
Nov 1813:15
Conference pass
INTASYL for adoptive cell therapy
Innovation Showcase (Track 2, Seminar Theatre)
Nov 1813:15
Conference pass
The Mygotic Process™ The Next Advancement in Autologous Totipotent Stem Cells from Somatic Cells
Cell Therapy (Track 1, Keynote Theatre)
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Nov 1813:15
Conference pass
Overview of the current US payer landscape: Where are we heading?
Evidence, Pricing & Access (Track 3, 120A)
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
Nov 1813:15
Conference pass
Kiji Therapeutics: Off-the-shelf, allogeneic engineered stem cell therapy for therapeutic payload delivery
Gene Modified Cell Therapy (Track 4, 120B)
Miguel Forte, CEO, Kiji Tx
Nov 1813:55
Conference pass
Gene therapy for cancer and inflammatory diseases
Gene Therapy (Track 5, 120C)
Shahrooz Rabizadeh, CEO & Co-Founder, Sagittarius Bio, Inc
Nov 1813:55
Conference pass
Latest advances in manufacturing technology
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Houman Dehghani, Vice President, Technical Development, Cabaletta Bio
Nov 1813:55
Conference pass
Logistical considerations when moving to a global based clinical trial
Supply Chain & Logistics (Track 8, 121 C)
Nov 1813:55
Conference pass
Revolutionizing Cardiac and Metabolic Disease Treatment with Gene Therapy Barriers with High-Yield, Low-Cost Manufacturing in Human and Animal Health
Viral Vector Manufacturing (Track 7, 121 B)
Daniel Oliver, Chief Executive Officer And Founder, Rejuvenate Bio
Nov 1813:55
Conference pass
Key considerations for success in investment and partnering in Biotech
Innovation Showcase (Track 2, Seminar Theatre)
Faizzan Ahmad, Chief Executive Officer, Cure8bio
Nov 1813:55
Conference pass
Treating neurologic conditions in children with cord blood and cord tissue derived therapies
Cell Therapy (Track 1, Keynote Theatre)
Joanne Kurtzberg, Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Nov 1813:55
Conference pass
Overcoming barriers to patient access for CAR-T therapies
Evidence, Pricing & Access (Track 3, 120A)
Michael Lehmicke, Sr. Vice President, Science & Industry Affairs, Alliance for Regenerative Medicine
Nov 1813:55
Conference pass
In vivo outcome of off-the-shelf engineered CIR™NK cells in multiple hematologic and solid tumors cells expressing HLA-G
Gene Modified Cell Therapy (Track 4, 120B)
Nov 1814:35
Conference pass
Analytical development for cell therapy manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Jie Wei, Director, Bioanalytical Sciences, Tr1x, Inc
Nov 1814:35
Conference pass
Building a supply chain to support RNA-based gene therapy development
Supply Chain & Logistics (Track 8, 121 C)
Qian Ruan, SVP of Technical Operations, Arcturus Therapeutics
Nov 1814:35
Conference pass
Life in the fast lane – working toward accelerated approval
Gene Therapy (Track 5, 120C)
Nov 1814:35
Conference pass
Workforce development for ATMPs
Viral Vector Manufacturing (Track 7, 121 B)
David Geoghegan, SVP, Head of Quality and Validation, Spark Therapeutics
David Zuzga, Associate Dean of Biomedical Studies, The Wistar Institute
Nov 1814:35
Conference pass
Harnessing Global HLA Data for Enhanced Patient Matching in iPSC Haplobanks
Cell Therapy (Track 1, Keynote Theatre)
Stephen Sullivan, Director, Lindville Bio
Nov 1814:35
Conference pass
Utilizing EU academic infrastructure for developing cell and gene therapies
Innovation Showcase (Track 2, Seminar Theatre)
David Morrow, Scientist, EATRIS
Nov 1814:35
Conference pass
Patient engagement in biopharma R&D
Evidence, Pricing & Access (Track 3, 120A)
Kimberly Neff, Principal, Big Magic
Nov 1814:35
Conference pass
In-vivo generation of therapeutic cells: CAR-T and beyond
Gene Modified Cell Therapy (Track 4, 120B)
David Peritt, Chief Scientific Officer, Lupagen
Nov 1815:15
Conference pass
Mutation agnostic gene therapy for neurodegenerative diseases
Gene Therapy (Track 5, 120C)
Samarendra Mohanty, President and Chief Scientific Officer, Nanoscope Therapeutics
Nov 1815:15
Conference pass
Novel platforms and processes for lentiviral vector production
Viral Vector Manufacturing (Track 7, 121 B)
Aziza Manceur, Research Officer, National Research Council Canada
Nov 1815:15
Conference pass
Optimizing Supply Chain and Logistics in Advanced Therapies Using Predictive Analytics
Supply Chain & Logistics (Track 8, 121 C)
Hemachandran Kannan, Director, Woxsen University
Nov 1815:15
Conference pass
Overview and Progress of CAR-T Cell Therapy Manufacturing Development
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Kaiyuan Jiang, Associate Director, API Cell Therapy, Johnson & Johnson Pharmaceutical R&D
Nov 1815:15
Conference pass
Best practice in process development
Cell Therapy (Track 1, Keynote Theatre)
Guangai Xue, Senior Scientist, Cell Therapy Technical Operations, Global Operations, AstraZeneca
Nov 1815:15
Conference pass
Delivering innovation in healthcare: Verismo Therapeutics
Innovation Showcase (Track 2, Seminar Theatre)
Pavel Aprelev, Director of Corporate Development, Verismo Therapeutics
Nov 1815:15
Conference pass
Market access considerations for Myeloma
Evidence, Pricing & Access (Track 3, 120A)
Jordan Schecter, Vice President | Multiple Myeloma DAS Leader, Johnson and Johnson
Mike Spencer, Vice President of Oncology Market Access, Johnson & Johnson
Nov 1815:15
Conference pass
Using platform technology to perform effective in vivo T-cell modification
Gene Modified Cell Therapy (Track 4, 120B)
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Nov 1815:35
Conference pass
Silver Sponsor (Sartorius BIA Separations)
Viral Vector Manufacturing (Track 7, 121 B)
Nov 1815:35
Conference pass
Emerging novel technologies to enable in vivo cell engineering as an alternative to traditional cell therapies
Gene Modified Cell Therapy (Track 4, 120B)
Paul Chen, Principal Research Scientist, AbbVie
Nov 1816:25
Conference pass
Chair's Remarks: Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Viral Vector Manufacturing (Track 7, 121 B)
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Nov 1816:25
Conference pass
Chair's Remarks: Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins School of Medicine
Gene Therapy (Track 5, 120C)
Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins Medicine
Nov 1816:25
Conference pass
Chair's Remarks: Priya Baraniak, Chief Commercial and Development Officer, Pluristyx
Supply Chain & Logistics (Track 8, 121 C)
Priya Baraniak, Chief Commercial and Development Officer, Pluristyx, Inc.
Nov 1816:25
Conference pass
Chair's Remarks: Stephanie Maistrellis, CEO + Partner, LEAD Life Sciences
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Stephanie Maistrellis, CEO, Lead Life Sciences
Nov 1816:25
Conference pass
Chair's Remarks: Lara Ionescu Silverman, Principal Consultant, LIS BioConsulting
Innovation Showcase (Track 2, Seminar Theatre)
Lara Silverman, Principal Consultant, Coeptis and LIS BioConsulting
Nov 1816:25
Conference pass
Chair's Remarks: Prachi Narayan, Global Q/C Stability Lead, Iovance Biotherapeutics, inc.
Cell Therapy (Track 1, Keynote Theatre)
Prachi Narayan, Global QC Stability Lead, Iovance Biotherapeutics
Nov 1816:25
Conference pass
Chair's Remarks: Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FDA
Evidence, Pricing & Access (Track 3, 120A)
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Nov 1816:25
Conference pass
Chair's Remarks: Marcus Calkins, Director of Scientific Communication, GenomeFrontier Therapeutics, Inc.
Gene Modified Cell Therapy (Track 4, 120B)
Marcus Calkins, Director of Scientific Communication, Genomefrontier Therapeutics Inc
Nov 1816:30
Conference pass
Applying established quality systems across the CGT supply chain
Supply Chain & Logistics (Track 8, 121 C)
Jeff Wren, Vice President, Biotherapies, AABB
Nov 1816:30
Conference pass
CMC strategy for late stage development of AAV-based gene therapy products
Viral Vector Manufacturing (Track 7, 121 B)
Arun Upadhyay, Chief Scientific Officer, Ocugen
Nov 1816:30
Conference pass
Leveraging AI to support manufacturing in life science cycle management
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Jared Auclair, Director of Bioinnovation, Northeastern university
Nov 1816:30
Conference pass
Novel riboswitch for gene therapy
Gene Therapy (Track 5, 120C)
Xuecui Guo, Director of Gene Regulation, Meiragtx
Nov 1816:30
Conference pass
ATOMIC: Administration of T-Cell Therapies with out-patient management in the community
Cell Therapy (Track 1, Keynote Theatre)
David Porter, Director, Cell Therapy and Transplant, University of Pennsylvania
Nov 1816:30
Conference pass
Constructs of Chemically Ligated Guide RNAs (LgRNA) for Precise Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Gene Editing
Innovation Showcase (Track 2, Seminar Theatre)
Nov 1816:30
Conference pass
Partnering with patient advocacy groups for the regulatory pathway and protecting access
Evidence, Pricing & Access (Track 3, 120A)
Brett Kopelan. MA, Executive Director, DebRa of America
Nov 1816:30
Conference pass
Allogenic stem cell therapies
Gene Modified Cell Therapy (Track 4, 120B)
Raisa Uchurova, Scientist, Century Therapeutics
Nov 1816:50
Conference pass
Preparing your early-phase supply chain for late-stage success
Supply Chain & Logistics (Track 8, 121 C)
Raymond Luke, Director, MSAT, Verismo Therapeutics
Nov 1816:50
Conference pass
Gene editing beyond the liver
Gene Modified Cell Therapy (Track 4, 120B)
Devyn Smith, CEO, Arbor Biotechnologies
Nov 1817:10
Conference pass
Panel Discussion: Applications for Gene Therapies
Gene Therapy (Track 5, 120C)
Moderator: Matt Killeen, President, TikkunLev Therapeutics
Dave Greenwald, Vice President Of Business Development, Deerfield Management
Eric Kmiec, Founder & CEO, CorriXR Therapeutics
Amy House, Head of Portfolio Strategy, Beacon Therapeutics
Kathryn Ivey, Senior Vice President of Research, Tenaya Therapeutics
Craig Martin, Founder, CEO, Orphan Therapeutics Accelerator
Sean Armour, SVP, Head of Discovery, Spark Therapeutics
Nov 1817:10
Conference pass
Panel Discussion: Building your supply chain from scratch
Supply Chain & Logistics (Track 8, 121 C)
Moderator: Jeff Wren, Vice President, Biotherapies, AABB
David Geoghegan, SVP, Head of Quality and Validation, Spark Therapeutics
Qian Ruan, SVP of Technical Operations, Arcturus Therapeutics
Brian Price, Chief Technology Officer, Armatus Bio, Inc
Christopher Ballas, Chief Technology Officer, Castle Creek Biosciences
Francesca Vitelli, Consultant, FPV Advisors
Raymond Luke, Director, MSAT, Verismo Therapeutics
Nov 1817:10
Conference pass
Panel Discussion: Staying agile and embracing technological innovations to optimize cell therapy manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Moderator: Nolan Polson, VP Quality Assurance and Product Quality, Iovance Biotherapeutics
Stephanie Maistrellis, CEO, Lead Life Sciences
Mark Dudley, Chief Scientific Officer, Instil Bio
Kaiyuan Jiang, Associate Director, API Cell Therapy, Johnson & Johnson Pharmaceutical R&D
Michael Lehmicke, Sr. Vice President, Science & Industry Affairs, Alliance for Regenerative Medicine
Craig Hasilo, Chief Scientific Officer, Canadian Advanced Therapies Training Institute
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
Sarah Yuan, Chief Technology Officer, Cabaletta Bio
Nov 1817:10
Conference pass
Panel Discussion: Streamlining process development
Viral Vector Manufacturing (Track 7, 121 B)
Moderator: Lior Raviv, CTO, Pluri
Michael Guerrero, Vice President of Technical Development and Operations, BridgeBio
Mi Jin, Head of Drug Substance, Spark Therapeutics
Yan Li, Senior Director, Process Development, Cabaletta Bio
James Adams, Chief Technical Officer, Tr1x, Inc
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
John Moscariello, Chief Technical Officer, Neuvogen Therapeutics
Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics
Nov 1817:10
Conference pass
Panel Discussion: Exploring the latest innovations and disruptions shaping cell therapy
Cell Therapy (Track 1, Keynote Theatre)
Moderator: Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Jose Eduardo Vidal, Chief Executive Officer, CytoImmune Therapeutics
Daniel KIlbank, CSO, Mygogenesis LLC
Prachi Narayan, Global QC Stability Lead, Iovance Biotherapeutics
Antoine Sreih, Vice President, Medical Director, Cullinan Therapeutics, Inc.
Deepu Madduri, Senior Director, Compound Development Team Lead, CARVYKTI, Johnson & Johnson
Eric Schuur, Chief Executive Officer, Hepatx Corporation
Xiao Huang, Assistant Professor, Precision Immune Engineering Laboratory, Drexel University
Nov 1817:10
Conference pass
Panel Discussion: Partnering and investment in Biotech
Innovation Showcase (Track 2, Seminar Theatre)
Moderator: Lara Silverman, Principal Consultant, Coeptis and LIS BioConsulting
Caralynn Collens, CEO, Dimension Inx
Fiona Miller, Managing Partner, quadraScope Ventures
Tracy Dowling, Chief Business Officer & General Counsel, AskBio
Susan Nichols, Chief Executive Officer, Propel Biosciences
Tom Lowery, President & CEO, Satellite Bio
Tay Salimullah, Venture Partner, 4BIO Capital
Nov 1817:10
Conference pass
Panel Discussion: Reimbursement challenges in delivering cures
Evidence, Pricing & Access (Track 3, 120A)
Kris Thiruvillakkat, Sr Director Global Market Access, CSL Behring
Jordan Schecter, Vice President | Multiple Myeloma DAS Leader, Johnson and Johnson
Melissa Penn, Director Patient Engagement Research & Development, Bayer
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
Stephanie Heathman, Business Development Lead, Opie Jones Foundation
Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, Food and Drug Administration (FDA)
Nov 1817:10
Conference pass
Panel Discussion: In vivo gene editing of immune cells - opportunities, challenges & alternative approaches
Gene Modified Cell Therapy (Track 4, 120B)
Moderator: David Peritt, Chief Scientific Officer, Lupagen
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Devyn Smith, CEO, Arbor Biotechnologies
Paul Chen, Principal Research Scientist, AbbVie
Daniel Dornbusch, CEO, Excision Biotherapeutics
Create your personal agenda –check the favourite icon
Nov 199:00
Conference pass
Chair’s Opening Remarks
Keynotes
Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, Perelman School of Medicine University of Pennsylvania
Nov 199:05
Conference pass
Keynote Panel Discussion: Overview of the current regulatory landscape for cell & gene therapies
Keynotes
Moderator: Heather Harte-Hall, Chief Compliance Officer, Cabaletta Bio
Jim Wang, VP, Global Regulatory Strategy, Genetic Medicines, Regeneron
Alexandra Beumer Sassi, Executive Director, CMC Regulatory Affairs, AstraZeneca
Christina Hartman, Senior Director, Government Affairs, Orchard Therapeutics
Raj Puri, Chief Regulatory Officer, Iovance Biotherapeutics
Nov 1910:05
Conference pass
Transforming treatment of autoimmune disease with effector T-cell therapy
Keynotes
Gwendolyn Binder, President of Science and Technology, Cabaletta Bio
Nov 1911:00
Conference pass
Roundtable 1: Patient identification for precision medicine gene therapy studies
Keynotes
Kirstin Liechty, Sr. Director, Clinical Operations, A2 Biotherapeutics
Nov 1911:00
Conference pass
Roundtable 10: Selecting the best antigens for cell therapy
Keynotes
Christopher Murriel, Vice President, Pre-Clinical Pharmacology, ArsenalBio
Nov 1911:00
Conference pass
Roundtable 11: Exploring the opportunities of technology transfer
Keynotes
Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute
Nov 1911:00
Conference pass
Roundtable 12: Analytical cell therapy bio-bank for cell therapy manufacturability
Keynotes
Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program
Nov 1911:00
Conference pass
Roundtable 2: How do we scale-up cell therapy manufacturing?
Keynotes
Rafal P. Witek, VP, Translational R&D, Head of Liver Program, Dimension Inx
Nov 1911:00
Conference pass
Roundtable 3: Operationalizing commercial cell therapies
Keynotes
Amy Pagliarulo, Senior Director Director of ATC Cell Therapy Operations, Iovance Biotherapeutics
Nov 1911:00
Conference pass
Roundtable 5: Exploring the role of AI-driven advanced analytics for manufacturing
Keynotes
Thorsten Gorba, VP, Process & Analytical Development, Aspen Neuroscience, Inc.
Nov 1911:00
Conference pass
Roundtable 6: Future-proofing talent acquisition: Workforce training strategies for Cell & Gene Therapy
Keynotes
David Zuzga, Associate Dean of Biomedical Studies, The Wistar Institute
Nov 1911:00
Conference pass
Roundtable 7: Creative deal-making and partnerships: Thriving in an evolving landscape
Keynotes
Priya Baraniak, Chief Commercial and Development Officer, Pluristyx, Inc.
Nov 1911:00
Conference pass
Roundtable 8: Navigating Trump 2.0
Keynotes
Lauren Martz, Executive Director, Biopharma Intelligence, BioCentury Inc
Nov 1911:00
Conference pass
Roundtable 9: End-to-end patient journey: Supply chain perspective
Keynotes
Pedro Rodriguez, Associate Director, Clinical Supply Operations, Johnson & Johnson
Nov 1913:00
Conference pass
Chair's Remarks: Kate Excoffon, VP Research, Spirovant Sciences
Gene Therapy (Track 5, 120C)
Nov 1913:00
Conference pass
Chair's Remarks: Martin Bonamino, Head of Cell & Gene Therapy Program, National Cancer Institute of Brazil
Patient Delivery (Track 8, 121C)
Nov 1913:00
Conference pass
Chair's Remarks: Omer Butt, VP, Regulatory Affairs, Cytoimmune
Regulatory Affairs & Policy (Track 3, 120A)
Omer Butt, Vice President, Regulatory Affairs, CytoImmune Therapeutics
Nov 1913:00
Conference pass
Chair's Remarks: Renaud Vaillant, CEO, Alaya.bio
Pre-Clinical (Track 4, 120B)
Renaud Vaillant, CEO & co-Founder, Alaya.bio
Nov 1913:00
Conference pass
Chair's Remarks: Thorsten Gorba, VP, Process & Analytical Development, Aspen Neuroscience
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Thorsten Gorba, VP, Process & Analytical Development, Aspen Neuroscience, Inc.
Nov 1913:00
Conference pass
Chair's Remarks: Yuntao Wu, Professor, George Mason University
Viral Vector Manufacturing (Track 7, 121 B)
Nov 1913:00
Conference pass
Chair's Remarks: Dana Silverbush, Assistant Professor of Cancer Biology, University of Pennsylvania
Innovation Showcase (Track 2, Seminar Theatre)
Dana Silverbush, Assistant Professor of Cancer Biology, University of Pennsylvania
Nov 1913:00
Conference pass
Chair's Remarks: Jakob Dupont, Executive Partner, Sofinnova Investment
Cell Therapy (Track 1, Keynote Theatre)
Nov 1913:05
Conference pass
AAV capsid engineering to improve delivery technologies for gene therapy applications
Gene Therapy (Track 5, 120C)
Quan Jin, Capsid Engineering Lead, Spark Therapeutics
Nov 1913:05
Conference pass
Accelerated development and approval of gene therapies
Regulatory Affairs & Policy (Track 3, 120A)
Keith Wonnacott, Vice President Regulatory Affairs, LEXEO Therapeutics
Nov 1913:05
Conference pass
Brazilian cell therapy landscape and joint initiatives
Patient Delivery (Track 8, 121C)
Stephan Kadauke, Associate Professor of Clinical Pathology and Lab Medicine, The Children's Hospital of Philadelphia
Nov 1913:05
Conference pass
Harnessing global HLA data for enhanced patient matching in IPSC Haplobanks
Pre-Clinical (Track 4, 120B)
Martin Maiers, VP, Research, NMDP
Nov 1913:05
Conference pass
Manufacturing under an accelerated development timeline
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Alexandra Beumer Sassi, Executive Director, CMC Regulatory Affairs, AstraZeneca
Nov 1913:05
Conference pass
Viral clearance for AAV
Viral Vector Manufacturing (Track 7, 121 B)
Wenjun Di, Senior Scientist, Ultragenyx Pharmaceutical Inc.
Nov 1913:05
Conference pass
Clinical phase I data: Use of gamma delta T-cell therapy in complex adult Leukaemias
Cell Therapy (Track 1, Keynote Theatre)
Kate Rochlin, Chief Operating Officer, IN8bio
Nov 1913:05
Conference pass
Harnessing technology to facilitate success in the manufacturing distribution space
Innovation Showcase (Track 2, Seminar Theatre)
Nov 1913:45
Conference pass
ADI-270: An allogeneic CAR gamma delta T cell therapy designed for enhanced potency against multiple oncology indications
Pre-Clinical (Track 4, 120B)
Shon Green, VP, Nonclinical Development, Adicet Bio
Nov 1913:45
Conference pass
Genethon: Developing gene therapy for rare diseases
Gene Therapy (Track 5, 120C)
Angela Columbano, Head Business Development Partnership, Genethon
Nov 1913:45
Conference pass
Improving patient access and survivorship
Patient Delivery (Track 8, 121C)
Nov 1913:45
Conference pass
Navigating Regulatory Challenges for the Development of Gene Therapy Products
Regulatory Affairs & Policy (Track 3, 120A)
Jim Wang, VP, Global Regulatory Strategy, Genetic Medicines, Regeneron
Nov 1913:45
Conference pass
Optimized process and analytical development plan for ocular gene therapies
Viral Vector Manufacturing (Track 7, 121 B)
Nov 1913:45
Conference pass
The impact of apheresis cryopreservation on CAR-T cell manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Yan Li, Senior Director, Process Development, Cabaletta Bio
Nov 1913:45
Conference pass
Innovation in CAR T therapy for solid tumours
Innovation Showcase (Track 2, Seminar Theatre)
Nov 1913:45
Conference pass
Precision bio materials for T-cell modulation
Cell Therapy (Track 1, Keynote Theatre)
Xiao Huang, Assistant Professor, Precision Immune Engineering Laboratory, Drexel University
Nov 1914:05
Conference pass
Panel Discussion: Best practice for patient centred clinical trial design
Pre-Clinical (Track 4, 120B)
Moderator: Renaud Vaillant, CEO & co-Founder, Alaya.bio
Joseph Stavas, Senior Vice President of Clinical Development, ProKidney
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Antoine Sreih, Vice President, Medical Director, Cullinan Therapeutics, Inc.
Kirstin Liechty, Sr. Director, Clinical Operations, A2 Biotherapeutics
Pedro Rodriguez, Associate Director, Clinical Supply Operations, Johnson & Johnson
Chris Tamburrini, Principal & Founder, RonanVance Search
Nov 1914:05
Conference pass
Panel Discussion: Delivering cell & gene therapies for patients in hospital and community settings
Patient Delivery (Track 8, 121C)
Moderator: Wenchun Qu, Associate Director of Centre for Regenerative Bio therapeutics in Florida, Mayo Clinic
Michael Mehler, Director, Cell Therapy Patient Operations, AstraZeneca
Saad Kenderian, Co Leader, Cancer Immunology and Immunotherapy, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic
Amy Pagliarulo, Senior Director Director of ATC Cell Therapy Operations, Iovance Biotherapeutics
Michael Storey, Former Medication Use Strategist, The Ohio State University and Nationwide Children’s Hospital
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
Madelyn Fell, Director of Operations, Cell Therapy and Transplant, University of Pennsylvania Health System
Micheala Jones, Lead, Global Medical Affairs, Hemophilia Gene Editing (CRISPR/Cas9) and Thrombosis, Regeneron
Nov 1914:05
Conference pass
Panel Discussion: IND preparedness for cell & gene therapies: Overcoming regulatory challenges
Regulatory Affairs & Policy (Track 3, 120A)
Moderator: Omer Butt, Vice President, Regulatory Affairs, CytoImmune Therapeutics
Keith Wonnacott, Vice President Regulatory Affairs, LEXEO Therapeutics
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Steven Highfill, Director of Product Development, Center for Cellular Engineering, Clinical Center, National Institutes of Health
Hugh Gannon, Associate Director, KSQ Therapeutics, Inc.
Nidhi Kotecha, Program Director, Regulatory Affairs, Gates Institute
Nov 1914:05
Conference pass
Panel Discussion: Innovations in Novel Capsids for Gene Therapies
Gene Therapy (Track 5, 120C)
Pedro Cejas, Head of New Therapeutic Modalities, Spark Therapeutics
Kathryn Ivey, Senior Vice President of Research, Tenaya Therapeutics
Arun Upadhyay, Chief Scientific Officer, Ocugen
Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson & Johnson Innovative Medicine
Angela Columbano, Head Business Development Partnership, Genethon
Nov 1914:05
Conference pass
Panel Discussion: Point-of-care manufacturing
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Moderator: Ashley Krull, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University Wexner Medical Center
Stephan Kadauke, Associate Professor of Clinical Pathology and Lab Medicine, The Children's Hospital of Philadelphia
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National institute of health
Stephanie Heathman, Business Development Lead, Opie Jones Foundation
Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program
Priya Baraniak, Chief Commercial and Development Officer, Pluristyx, Inc.
Nov 1914:05
Conference pass
Panel Discussion: Understanding the Evolving Landscape of Viral Vector
Viral Vector Manufacturing (Track 7, 121 B)
Moderator: Jenny Holt, Chief Development Officer, Ray Therapeutics
Michael McMahon, Professor, John Hopkins School Of Medicine
Daniel Cohen, Head of Vector Optimization, Spark Therapeutics
Aziza Manceur, Research Officer, National Research Council Canada
Nov 1914:05
Conference pass
Panel Discussion: Company Creation in ATMPs
Innovation Showcase (Track 2, Seminar Theatre)
Moderator: Angela Justice, Chief People Officer / Executive Advisor, Justice Group Advisors
Eric Hacherl, Chief Operating Officer, Kyttaro Therapeutics
Fiona Miller, Managing Partner, quadraScope Ventures
Petter Bjorquist, CEO, VERIGRAFT AB
Hernando Lopez-Bertoni, Associate Professor, Johns Hopkins Medicine
Lauren Martz, Executive Director, Biopharma Intelligence, BioCentury Inc
Susan Nichols, Chief Executive Officer, Propel Biosciences
Eric Schuur, Chief Executive Officer, Hepatx Corporation
Sareina Wu, Founder & CSO, Genomefrontier Therapeutics Inc
Nov 1914:05
Conference pass
Panel Discussion: Ex vivo vs In vivo cell engineering
Cell Therapy (Track 1, Keynote Theatre)
Moderator: Rafal P. Witek, VP, Translational R&D, Head of Liver Program, Dimension Inx
Raisa Uchurova, Scientist, Century Therapeutics
Holger Russ, Associate Professor, University of Florida
Arnaud Deladeriere, President and Principal Consultant, Cell&Gene Consulting
Christopher Murriel, Vice President, Pre-Clinical Pharmacology, ArsenalBio
Daniel Baker, PhD Candidate, June Lab, University of Pennsylvania School Of Medicine
Parimal Pande, Associate Scientific Director, Johnson & Johnson
Nov 1915:15
Conference pass
Chair's Remarks: Daniel Weiss, Professor of Medicine, Pulmonary Medicine Department of Medicine, University of Vermont and, President-Elect, ISCT
Clinical (Track 4, 120B)
Daniel Weiss, Professor of Medicine, Pulmonary Medicine Department of Medicine, University of Vermont
Nov 1915:15
Conference pass
Chair's Remarks: Martin Bonamino, Head of Cell & Gene Therapy Program, National Cancer Institute of Brazil
Patient Delivery (Track 8, 121C)
Nov 1915:15
Conference pass
Chair's Remarks: Matthias Stöcker, Regulatory Capability Lead, Boehringer Ingelheim International
Regulatory Affairs & Policy (Track 3, 120A)
Matthias Stöcker, Regulatory Capability Lead, Boehringer Ingelheim International GmbH
Nov 1915:15
Conference pass
Chair's Remarks: Nirav Shah, Associate Professor of Medicine, Director, BMT & Cellular Therapy Program, Medical College of Wisconsin
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Nirav Shah, Associate Professor of Medicine, Director, BMT & Cellular Therapy Program, Medical College of Wisconsin
Nov 1915:15
Conference pass
Chair's Remarks: Pedro Cejas, Senior Director, Head of New Therapeutic Modalities, Spark Therapeutics
Gene Therapy (Track 5, 120C)
Pedro Cejas, Head of New Therapeutic Modalities, Spark Therapeutics
Nov 1915:15
Conference pass
Chair's Remarks: Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson and Johnson Innovative Medicine
Viral Vector Manufacturing (Track 7, 121 B)
Seema Bhatlekar, Senior Scientist, Gene Therapy Process Development, Johnson & Johnson Innovative Medicine
Nov 1915:15
Conference pass
Chair's Remarks: Angela Justice, Founder, Justice Group Advisors
Innovation Showcase (Track 2, Seminar Theatre)
Angela Justice, Chief People Officer / Executive Advisor, Justice Group Advisors
Nov 1915:15
Conference pass
Chair's Remarks: Rafal P. Witek, Senior Director of R&D Engineering, Dimension Inx
Cell Therapy (Track 1, Keynote Theatre)
Rafal P. Witek, VP, Translational R&D, Head of Liver Program, Dimension Inx
Nov 1915:20
Conference pass
Considerations for immunologic monitoring of AAV gene therapy clinical trials
Clinical (Track 4, 120B)
Simon Lacey, Vice President - Immunology, Asklepios BioPharmaceutical, Inc. (AskBio)
Nov 1915:20
Conference pass
Impact of ITR quality on AAV manufacturing
Viral Vector Manufacturing (Track 7, 121 B)
Daniel Cohen, Head of Vector Optimization, Spark Therapeutics
Nov 1915:20
Conference pass
In Vivo and Ex vivo cell and gene therapies operational oversight
Patient Delivery (Track 8, 121C)
Mark Duckworth, Sr. Director Cellular and Gene Therapy Operations, Children's Hospital of Philadelphia
Nov 1915:20
Conference pass
pH-dependent DNA degradation pathways for adeno-associated virus gene therapy
Gene Therapy (Track 5, 120C)
Kimberly Malecka, Senior Scientist, Spark Therapeutics
Nov 1915:20
Conference pass
Tech transfer to an academic cell therapy manufacturing lab
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Ashley Krull, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University Wexner Medical Center
Nov 1915:20
Conference pass
The Importance of Interacting with Regulators
Regulatory Affairs & Policy (Track 3, 120A)
Margareth Jorvid, Head of Regulatory Affairs, Ilya Pharma
Nov 1915:20
Conference pass
Allogenic CAR-T therapies
Cell Therapy (Track 1, Keynote Theatre)
Sean O'Brien, Senior Scientist, AstraZeneca
Nov 1915:20
Conference pass
Transposon-Based CAR-T cells
Innovation Showcase (Track 2, Seminar Theatre)
Luiza Abdo, Doctor, Brazilian National Cancer Institute
Nov 1915:40
Conference pass
Exploring the role of AI-driven advanced analytics for manufacturing of ATMPs
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Thorsten Gorba, VP, Process & Analytical Development, Aspen Neuroscience, Inc.
Nov 1915:40
Conference pass
Improving Access to Cell and Gene Therapies
Patient Delivery (Track 8, 121C)
Madelyn Fell, Director of Operations, Cell Therapy and Transplant, University of Pennsylvania Health System
Nov 1915:40
Conference pass
Regulatory challenges of ATMPs in clinical development
Regulatory Affairs & Policy (Track 3, 120A)
Matthias Stöcker, Regulatory Capability Lead, Boehringer Ingelheim International GmbH
Nov 1915:40
Conference pass
Clinical development of NK cell therapies
Cell Therapy (Track 1, Keynote Theatre)
Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics
Nov 1916:00
Conference pass
Best practice in patient operations: seamless cell therapy journey for patients
Patient Delivery (Track 8, 121C)
Michael Mehler, Director, Cell Therapy Patient Operations, AstraZeneca
Nov 1916:00
Conference pass
Clinical Biomarkers of durable response to ciltacaptagene autoleucel in multiple myeloma patients
Clinical (Track 4, 120B)
Vicki Plaks, Senior Scientific Director and Head of Cell Therapy, Oncology Translational Research, Johnson & Johnson
Nov 1916:00
Conference pass
Manufacturing for genetically modified cell products
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Friederike Herbst-Nowrouzi, Director of the Human Genome Editing Laboratory (HGEL), Perelman School of Medicine University of Pennsylvania
Nov 1916:00
Conference pass
Mindset and skillset revolution in hiring to meet the emerging workforce needs
Viral Vector Manufacturing (Track 7, 121 B)
Vishal Shah, Dean, Division of the Math, Science and Health Careers, Community College of Philadelphia
Nov 1916:00
Conference pass
Model-based dosing of the conditioning in cell & gene therapy
Gene Therapy (Track 5, 120C)
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Nov 1916:00
Conference pass
Recent trends in new born screening
Regulatory Affairs & Policy (Track 3, 120A)
Dave Greenwald, Vice President Of Business Development, Deerfield Management
Nov 1916:00
Conference pass
Pan-tissue master regulator inference reveals mechanisms of MHC alterations in cancers
Innovation Showcase (Track 2, Seminar Theatre)
Mahnoor Gondal, PhD Candidate, University of Michigan
Nov 1916:00
Conference pass
Tregulatory cell therapies: Clinical experience and the next generation of engineered Tregs
Cell Therapy (Track 1, Keynote Theatre)
Daniel Shelly, Chief Business Development Officer, PolTREG AG
Nov 1916:20
Conference pass
Academic and industry collaboration to develop novel cell therapies
Cell Therapy Manufacturing Sponsored by Terumo Blood and Cell Technologies (Track 6, 121A)
Nirav Shah, Associate Professor of Medicine, Director, BMT & Cellular Therapy Program, Medical College of Wisconsin
Nov 1916:20
Conference pass
CRISPR directed in vivo gene editing for head & neck cancer
Gene Therapy (Track 5, 120C)
Eric Kmiec, Founder & CEO, CorriXR Therapeutics
Nov 1916:20
Conference pass
Designing a robust commercial control strategy for viral vector manufacturing
Viral Vector Manufacturing (Track 7, 121 B)
Nov 1916:20
Conference pass
Latest update for MSC clinical trials
Clinical (Track 4, 120B)
Daniel Weiss, Professor of Medicine, Pulmonary Medicine Department of Medicine, University of Vermont
Nov 1916:20
Conference pass
Regulatory reform for ultrarare disease drug development
Regulatory Affairs & Policy (Track 3, 120A)
Lisa Kahlman, Executive Director, Public Policy & Public affairs, Ultragenyx Pharmaceutical Inc.
Nov 1916:20
Conference pass
Speaking the language of patients: Empowering patients through medical lexicon
Patient Delivery (Track 8, 121C)
Micheala Jones, Lead, Global Medical Affairs, Hemophilia Gene Editing (CRISPR/Cas9) and Thrombosis, Regeneron
Nov 1916:20
Conference pass
Best practice in quality control for cell therapies
Cell Therapy (Track 1, Keynote Theatre)
Anthony Garcia, Chief Quality Officer, AstroBio Solutions
Nov 1916:20
Conference pass
Biomimetic Digital Twins and Multiomics: To Identify New Therapeutic Targets and to Reduce the Time and Cost of Drug Development
Innovation Showcase (Track 2, Seminar Theatre)
William Kearns, Chief Executive Officer and CSO, Genzeva
last published: 29/Apr/25 14:25 GMT
Get Involved with the Advanced Therapies Congress
To sponsor or exhibit
Natasha Bangle
natasha.bangle@terrapinn.com
+44 20 3545 5515
Joshua Lloyd
Josh.Lloyd@terrapinn.com
+44 20 4614 9423
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events